PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study reveals new genetic link between anorexia nervosa and being an early riser

Individuals with the eating disorder often wake early and experience insomnia.

2024-01-04
(Press-News.org) BOSTON – New research indicates that the eating disorder anorexia nervosa is associated with being an early riser, unlike many other disorders that tend to be evening-based such as depression, binge eating disorder and schizophrenia.

The study, which is published in JAMA Network Open and led by investigators at Massachusetts General Hospital (MGH), in collaboration with University College London and the University of the Republic in Uruguay, also revealed a link between anorexia nervosa and insomnia risk.

Previous research has suggested a possible connection between eating disorders and the body’s internal clock, or circadian clock, which controls a wide range of biological functions such as sleep and affects nearly every organ in the body.

This study aimed to further understand this relationship by assessing genes associated with anorexia nervosa, the circadian clock and several sleep traits including insomnia.

The investigators used a statistical method called Mendelian Randomization to see how genes that are associated with a certain trait affect other traits of interest. For example, examining the sleep patterns of people with genetic differences that makes them more likely to have anorexia nervosa, this provides evidence on the relationship between anorexia nervosa and sleep.

They found a two-way association between genes associated with anorexia nervosa and genes associated with morning chronotype (waking early and going to bed early).

In other words, the findings suggest that being an early riser could increase the risk for having anorexia nervosa, and having anorexia nervosa could lead to an earlier wake time. The team also found an association between anorexia nervosa and insomnia.

When they further assessed the insomnia connection using the Mass General Brigham Biobank by developing a “genetic risk score” for anorexia nervosa, the scientists found that the genetic risk score was indeed associated with higher insomnia risk.

“Our findings implicate anorexia nervosa as a morning disorder in contrast to most other evening-based psychiatric diseases and support the association between anorexia nervosa and insomnia as seen in earlier studies,” says senior author Hassan S Dashti, PhD, RD, an assistant investigator in the Department of Anesthesia, Critical Care and Pain Medicine at MGH and an assistant professor of anesthesia at Harvard Medical School.

Treatments for anorexia nervosa are limited and current treatments have relapse rates of up to 52%. In addition, the cause of the disease is still unclear.

With anorexia nervosa having the second highest mortality rate of psychiatric diseases, more research is desperately needed into new prevention strategies and treatments.

“The clinical implications of our new findings are currently unclear; however, our results could direct future investigations into circadian-based therapies for anorexia nervosa prevention and treatment,” says Hannah Wilcox, lead author of the study and researcher at MGH.

 

Additional authors include Valentina Paz, MSc, Richa Saxena, PhD, John W. Winkelman, MD, PhD, and Victoria Garfield, PhD.

 

This research was supported by the National Institutes of Health.

 

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In July 2022, Mass General was named #8 in the U.S. News & World Report list of "America’s Best Hospitals." MGH is a founding member of the Mass General Brigham healthcare system.

END


ELSE PRESS RELEASES FROM THIS DATE:

Immune atlas at cell level points to new combination treatment for incurable childhood cancer

2024-01-04
Press release: Princess Máxima Center for pediatric oncology EMBARGO: JANUARY 4, 2024 AT 11:00 AM ET (US)   A detailed 'atlas' of neuroblastoma tumors points to a new target for immunotherapy. Scientists from the Princess Máxima Center for pediatric oncology in the Netherlands mapped this childhood tumor at the level of individual cancer and immune cells. In doing so, they discovered a brake on the immune system that can be blocked with existing immunotherapy. The results in the lab are promising; preparations for a clinical study are underway. Every year, 25 children in the Netherlands ...

The Colorado Center for Personalized Medicine highlighted as a leader in precision medicine in research and clinical care

2024-01-04
A new peer-reviewed study in the American Journal of Human Genetics highlights the work of the biobank at the Colorado Center for Personalized Medicine (CCPM), a world-class site for precision medicine in research and clinical care created in partnership with the University of Colorado Anschutz Medical Campus and UCHealth. The paper focuses on CCPM’s research and personalized medical care.   “We’re one of the only institutions in the world that has accomplished the dual-purpose of using genetic information to accelerate scientific discovery in research while providing actionable clinical results to patients that ...

Treating tuberculosis when antibiotics no longer work

2024-01-04
In cooperation with research partners in Germany and France, the infectious disease specialist Dr Jan Rybniker and his team at University Hospital Cologne and the University of Cologne’s Faculty of Medicine have identified new, antibiotic molecules that target Mycobacterium tuberculosis and make it less pathogenic for humans. In addition, some of the discovered substances may allow for a renewed treatment of tuberculosis with available medications – including strains of the bacterium that have already developed drug resistance. The research has been published in the article ‘Discovery of dual-active ethionamide boosters ...

Supercharging CAR-T cells for cancer treatment

2024-01-04
At EPFL's School of Engineering, Professor Li Tang's Laboratory of Biomaterials for Immunoengineering has made significant strides in cancer treatment research. In laboratory settings, this innovative CAR-T therapy has consistently eradicated cancerous tumors in mouse models. Separately, in on-going clinical trials, eleven patients seemed to achieve complete remission using this treatment, marking a success rate of 100% to date. Notably, evidence from the lab study, published in Nature Biotechnology, suggests the therapy's long-term effectiveness, and indicates that its fabrication may be both quicker and more cost-effective ...

Minimizing immunotherapy’s potentially harmful side effects

Minimizing immunotherapy’s potentially harmful side effects
2024-01-04
MIAMI, FLORIDA (EMBARGOED UNTIL JAN. 4, 2024, at 10 AM EST) – Recent advances in treating multiple myeloma, the second most common blood cancer, and other blood malignancies are providing improved outcomes – and hope – to patients worldwide. But treatment breakthroughs such as the immunotherapy drug teclistamab can lead to potentially lethal side effects, including cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS). These potential side effects have necessitated giving immunotherapy drugs in the hospital setting, where patients remain for five to seven days and receive other drugs ...

Study finds paxlovid treatment does not reduce risk of long COVID

2024-01-04
A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection. They also found a higher proportion of individuals with acute symptoms rebound and test-positivity than previously reported. The study appears Jan. 4, 2024, in the Journal of Medical Virology. Paxlovid treatment for acute COVID-19 has been shown to be effective for high-risk unvaccinated individuals. But the effect of the treatment on long COVID risk, including whether it protects vaccinated people from getting long COVID, has been less clear. The ...

Menarini Group and Insilico Medicine enter global exclusive license agreement for novel KAT6 inhibitor for potential breast cancer treatment and other oncology indications

Menarini Group and Insilico Medicine enter global exclusive license agreement for novel KAT6 inhibitor for potential breast cancer treatment and other oncology indications
2024-01-04
● KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. ● The molecule has demonstrated strong preclinical activity. Insilico Medicine presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December. ● This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties. FLORENCE, Italy and NEW YORK: The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, ...

New population risk prediction model for likelihood of ICU admission and survival

2024-01-04
INDIANAPOLIS – A significant obstacle to improving care and outcomes for intensive care unit (ICU) patients is the unexpected nature of becoming seriously ill. Which groups of patients are likely to become severely ill and will they survive their ICU stay? In a first step in creating infrastructure for further studies to identify and follow cohorts of patients who may become critically ill, researchers including Sikandar Khan, D.O, M.S., of Regenstrief Institute and Indiana University School of Medicine, have developed and conducted ...

Chung-Ang University study reveals a higher market valuation of cash holdings of firms adopting electronic voting

Chung-Ang University study reveals a higher market valuation of cash holdings of firms adopting electronic voting
2024-01-04
Firms worldwide are increasingly adopting electronic voting, enabling shareholders to cast their votes online, instead of attending shareholder meetings in-person. Shareholders can enjoy superior accessibility to the meetings with electronic voting, compared to those with traditional and in-person setups. Despite the emerging popularity of electronic voting in recent years, however, there is limited evidence of its impact on governance. To address this gap in research, Associate Professor Wonsuk Ha from the School of Business Administration, Chung-Ang University, along ...

Women undergoing fertility treatment who are stressed may have heart health issues during pregnancy

2024-01-04
WASHINGTON—A new Journal of the Endocrine Society study among women attending a fertility center found that those with more stress before pregnancy had higher blood sugar levels during pregnancy, which is a sign of weaker cardiovascular health. People’s stress levels have continued to rise over the years, particularly in the last few years due to the COVID-19 pandemic, putting them at risk for serious health issues such as heart disease. Research shows women may experience more stress than men, especially those going through infertility. Maintaining a healthy pregnancy ...

LAST 30 PRESS RELEASES:

Children born with upper limb difference show the incredible adaptability of the young brain

How bacteria can reclaim lost energy, nutrients, and clean water from wastewater

Fast-paced lives demand faster vision: ecology shapes how “quickly” animals see time

Global warming and heat stress risk close in on the Tour de France

New technology reveals hidden DNA scaffolding built before life ‘switches on’

New study reveals early healthy eating shapes lifelong brain health

Trashing cancer’s ‘undruggable’ proteins

Industrial research labs were invented in Europe but made the U.S. a tech superpower

Enzymes work as Maxwell's demon by using memory stored as motion

Methane’s missing emissions: The underestimated impact of small sources

Beating cancer by eating cancer

How sleep disruption impairs social memory: Oxytocin circuits reveal mechanisms and therapeutic opportunities

Natural compound from pomegranate leaves disrupts disease-causing amyloid

A depression treatment that once took eight weeks may work just as well in one

New study calls for personalized, tiered approach to postpartum care

The hidden breath of cities: Why we need to look closer at public fountains

Rewetting peatlands could unlock more effective carbon removal using biochar

Microplastics discovered in prostate tumors

ACES marks 150 years of the Morrow Plots, our nation's oldest research field

Physicists open door to future, hyper-efficient ‘orbitronic’ devices

$80 million supports research into exceptional longevity

Why the planet doesn’t dry out together: scientists solve a global climate puzzle

Global greening: The Earth’s green wave is shifting

You don't need to be very altruistic to stop an epidemic

Signs on Stone Age objects: Precursor to written language dates back 40,000 years

MIT study reveals climatic fingerprints of wildfires and volcanic eruptions

A shift from the sandlot to the travel team for youth sports

Hair-width LEDs could replace lasers

The hidden infections that refuse to go away: how household practices can stop deadly diseases

Ochsner MD Anderson uses groundbreaking TIL therapy to treat advanced melanoma in adults

[Press-News.org] Study reveals new genetic link between anorexia nervosa and being an early riser
Individuals with the eating disorder often wake early and experience insomnia.